Arqule shares plunged $3.09, or 62%, to $1.90 in Tuesday's pre-market session.
At its current burn rate, Arqule has approximately $1.75 per share in cash.
The phase III "MARQUEE" study enrolled 1,000 patients with newly diagnosed non-small cell lung cancer and randomized them to receive either tivantinib plus Tarceva or Tarceva alone. Tarceva is a currently approved treatment for lung cancer marketed by Roche (RHHBY) and Astellas.After a planned interim analysis, independent monitors concluded that tivantinib would fail to improve overall survival compared to Tarceva -- the primary endpoint of the study. On that basis, Arqule and its partner Daiichi Sankyo decided to discontinue the study. "We are disappointed that the MARQUEE trial did not provide statistically significant results for overall survival in a disease and treatment setting which remains a major unmet medical need," said Paolo Pucci, Arqule CEO, in a statement. Arqule said nothing Tuesday about the status of a separate phase III study of tivantinib being conducted in Asia. That study, known as "ATTENTION" stopped enrolling patients in August due to reports of suspected cases if interstitial lung disease that appeared to be more prevalent in patients treated with tivantinib. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV